Company name: AccUrine
Website: https://accurine.co/

CEO name: Yael Schnedmann

CATEGORY: Medical Devices

SESSION: "From Detection to Prediction: Diagnosing Disease Before Symptoms."

Executive Summary / Investment Rational:
AccUrine Ltd. develops simple, low-cost, self-use urine tests based on proteomic signatures reflecting systemic conditions. The approach decentralizes laboratory infrastructure, enabling rapid decision-making at home and point-of-care. Progress includes validated signatures and functional prototypes. Supported by clinical collaborations and early funding, the team combines clinical, proteomics, and assay development expertise.

Core Technology:
A proprietary urine proteomics engine identifies minimal biomarker signatures (1–3 proteins) capturing systemic physiological states, then translates them into lateral flow assays using urine-adapted antibodies. Uniqueness: extracting clinically meaningful systemic signals from urine. Value: non-invasive, rapid, repeatable testing enabling real-time and longitudinal clinical decision support.

Product Profile/Pipeline:
Pipeline includes kits for bacterial vs. viral differentiation in upper respiratory tract infections, detection of severe systemic inflammation, and heart failure (HF) diagnosis and monitoring of exacerbations, all based on compact protein signatures. Two lead products are advancing as lateral flow tests, with prototypes demonstrating proven sensitivity (LOD) in clinical urine samples and ongoing multicenter validation to establish clinical performance and utility.

Business Strategy:
AccUrine targets decentralized care via providers, payers, and telehealth channels. Initial focus is high-impact triage indications, followed by expansion into broader systemic conditions. The model leverages scalable manufacturing partnerships, regulatory pathways (FDA/CE/AMAR), and a menu expansion strategy based on the same proteomic engine.

What's Next?
Near-term priorities focus on the first product kit for detection of severe systemic inflammation, including optimization of prototype performance and advancement of regulatory approval pathways, alongside continued clinical validation and manufacturing readiness to support commercialization.